Tags: Chemical Compound, Chemical Substance.

Ombrabulin is an experimental drug candidate discovered by Ajinomoto and under development by Sanofi-Aventis. It is currently in Phase III clinical trials for the treatment of advanced-stage soft-tissue sarcoma.Ombrabulin was granted orphan drug status by the European Medicines Agency in April 2011.Ombrabulin is a combretastatin A-4 derivative that exerts its antitumor effect by disrupting the formation of blood vessels needed for tumor growth.

Ombrabulin.svg
IUPAC name
(2S)-2-Amino-3-hydroxy-N-[2-methoxy-5-[(Z)-2-(345-trimethoxyphenyl)ethenyl]phenyl]propanamide

Loading...

This page contains content from the copyrighted Wikipedia article "Ombrabulin"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.